This paper is only available as a PDF. To read, Please Download here.
Abstract
The long-term efficacy and safety of risperidone were evaluated in patients with chronic
schizophrenia in an open-label study. Thirty-two patients received risperidone for
1 year and 19 of the 32 received risperidone for 2 years. The mean dose of risperidone
was 9.4 mg/d in the 1-year follow-up and 8 mg/d in the 2-year follow-up. At the end
of 1 and 2 years, improvements were found in total scores on the Positive and Negative
Syndrome Scale (PANSS), on four PANSS factors (positive, negative, excited, and cognitive),
and the Clinical Global Impression scale. Severity of extrapyramidal symptoms (based
on scores on the Extrapyramidal Symptom Rating Scale) was also reduced. Clinical improvement
(defined as a 20% or more reduction in total PANSS scores) was shown by 54% of the
patients at end point. Social functioning (as assessed by using the modified Straus/Carpenter
scale) was significantly improved after 2 years. Number of days spent in hospitals
was significantly reduced during the 2 years of treatment, and the number of days
in treatment (group) homes significantly increased. It is concluded that treatment
with risperidone for 1 and 2 years is associated with significant reductions in symptoms
of schizophrenia, improved social functioning, and reduction in days spent in the
hospital.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
Peuskens J. The Risperidone Study Group. Risperidone in the treatment of chronic schizophrenic patients: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry. In press.
- Risperidone: Clinical safety and efficacy in schizophrenia.Psychopharmacol Bull. 1992; 28: 213-218
- A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.J Clin Psychopharmacol. 1993; 13: 25-40
- Risperidone in the treatment of schizophrenia.Am J Psychiatry. 1994; 151: 825-835
- Third Edition. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, Washington, DC1987 (Revised)
- The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.Schizophr Bull. 1987; 13: 261-276
- Principal component analysis of the Swedish version of the Positive and Negative Syndrome Scale for schizophrenia.Nord J Psychiatry. 1999; 47: 257-263
- Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol.Pharmacopsychiatry. 1993; 27: 108-113
- Five-factor model of schizophrenia; initial validation.J Nerv Ment Dis. 1994; 182: 631-638
- Guy W ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health, Rockville, Md1976 (Publication ADM 76-338)
- Extrapyramidal Symptom Rating Scale.Can J Neurol Sci. 1980; 7: 233
- The prediction of outcome in schizophrenia.Arch Gen Psychiatry. 1972; 27: 739-746
- Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates.Arch Gen Psychiatry. 1974; 31: 603-608
- Prevention of relapse in schizophrenia: An evaluation of fluphenazine decanoate.Arch Gen Psychiatry. 1980; 37: 16-24
- Fluphenazine and social therapy in the aftercare of schizophrenic patients: Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride.Arch Gen Psychiatry. 1979; 36: 1283-1294
- Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes.Arch Gen Psychiatry. 1983; 40: 1113-1117
- Welfare and Free Choice. Allmänna Förlaget, SOU, Stockholm, Sweden1992: 73
- Reduction in hospital days in chronic schizophrenic patients treated with risperidone: A retrospective study.Clin Ther. 1993; 15: 917-926
Article info
Identification
Copyright
© 1995 Published by Elsevier Inc.
